We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novacea announced the Journal of Clinical Oncology (JCO) has published findings from the large Phase II ASCENT trial of its lead investigational cancer therapy, DN-101 or Asentar.
CeNeS Pharmaceuticals has announced preliminary results from a pivotal Phase III trial of morphine-6-glucuronide (M6G) in more than 500 patients with postoperative pain.
Cardiome Pharma and its co-development partner Astellas Pharma announced that the FDA has accepted for review their new drug application (NDA) for the intravenous formulation of vernakalant hydrochloride for the acute conversion of atrial fibrillation.
Can-Fite BioPharma has announced preclinical study results showing that CF102 is active against hepatitis B virus, in addition to liver cancer, which is the first indication for which the drug is being developed.
AlphaVax's novel alphavaccine technology has been shown to be effective in generating protection against congenital cytomegalovirus (CMV) disease in a preclinical study published in the March 15 issue of the Journal of Infectious Diseases.
Transgene announced that the first patients have been enrolled in a Phase I trial of its therapeutic vaccine candidate TG4040 (MVA-HCV) for patients chronically infected with the hepatitis C virus (HCV).